Graft Enhancement, Immunologic
"Graft Enhancement, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The induction of prolonged survival and growth of allografts of either tumors or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunized donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity.
| Descriptor ID |
D006082
|
| MeSH Number(s) |
E02.095.465.425.450.440 E05.478.610.500
|
| Concept/Terms |
Graft Enhancement, Immunologic- Graft Enhancement, Immunologic
- Immunologic Graft Enhancement
- Graft Enhancement, Immunological
- Enhancement, Immunological Graft
- Enhancements, Immunological Graft
- Graft Enhancements, Immunological
- Immunological Graft Enhancement
- Immunological Graft Enhancements
- Enhancement, Immunologic Graft
- Enhancements, Immunologic Graft
- Graft Enhancements, Immunologic
- Immunologic Graft Enhancements
- Immunologic Enhancement of Grafts
Graft Enhancement- Graft Enhancement
- Enhancement, Graft
- Enhancements, Graft
- Graft Enhancements
|
Below are MeSH descriptors whose meaning is more general than "Graft Enhancement, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Graft Enhancement, Immunologic".
This graph shows the total number of publications written about "Graft Enhancement, Immunologic" by people in this website by year, and whether "Graft Enhancement, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 0 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2002 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Graft Enhancement, Immunologic" by people in Profiles.
-
Conventional and novel approaches to immunosuppression. Clin Chest Med. 2011 Jun; 32(2):265-77.
-
Prolongation of cardiac allograft survival by systemic administration of immature recipient dendritic cells deficient in NF-kappaB activity. Ann Surg. 2005 Mar; 241(3):497-505.
-
Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol. 2002 Sep 15; 169(6):3382-91.
-
Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance. J Immunol. 2000 Nov 15; 165(10):5580-7.
-
A clinical trial combining donor bone marrow infusion and heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg. 2000 Apr; 119(4 Pt 1):673-81.
-
Enhanced engraftment of human peripheral blood lymphocytes into anti-murine interferon-gamma monoclonal antibody-treated C.B.-17-scid mice. Cell Immunol. 1998 Jan 10; 183(1):60-9.
-
Chimerism after organ transplantation. Curr Opin Nephrol Hypertens. 1997 May; 6(3):292-8.
-
An attempt to induce tolerance with infusion of donor bone marrow in organ allograft recipients. Adv Exp Med Biol. 1997; 417:269-74.
-
An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol. 1995 Aug 01; 155(3):1544-55.
-
Inhibition of transplant rejection by pretreatment of xenogeneic pancreatic islet cells with anti-ICAM-1 antibodies. Transplantation. 1994 Sep 27; 58(6):681-9.